HARMONY will be attending the next annual meeting of the American Society of Hematology (ASH) in Florida (December 7–10, 2019). We will be discussing the latest scientific advances across HARMONY’s research projects and thinking about how HARMONY can be utilized to address additional research needs and improve care for patients.
Our breakfast morning will be held in Room Manatee Spring 1 at 06:00 on December 8 – click here to view the agenda.
Join us and share your views on how we can enable better and faster treatment for patients with HMs; or contact us if you would like to arrange a direct meeting.
You can also find more information about HARMONY at the European Hematology Association (EHA) exhibition (booth number 250). EHA is one of the 53 HARMONY Alliance Partners.
The ASH Annual Meeting provides a unique platform whereby hematology professionals can exchange knowledge and expertise on a wide range of topics. This event will present the latest scientific discoveries in the field of hematology and explore strategies to improve clinical practice and patient outcomes. Click here to visit the official ASH congress website.
ASH has accepted HARMONY’s abstract titled, ‘Validation and Improvement Opportunities of the Revised International Staging System for Multiple Myeloma: An Analysis on Mature Data from European Clinical Trials Within the HARMONY Big Data Platform’ – click here to view the abstract.
The research will be presented during the poster viewing session at 17:30–19:30 on Saturday December 7, Session 651, Hall B Level 2, Orange County Convention Center.
This study was made possible by the wealth of data in the HARMONY Big Data Platform – 5584 patient datasets were available.
Become involved with HARMONY today! Contact us to find out how you can participate in ongoing and future research initiatives.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
